Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1981 1
1984 1
1986 1
1987 2
1990 2
1991 2
1995 2
1999 1
2000 2
2002 1
2005 3
2006 1
2010 1
2011 1
2012 2
2013 1
2014 1
2016 3
2017 3
2019 1
2020 2
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Chung EY, et al. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4. Cochrane Database Syst Rev. 2020. PMID: 33107592 Free PMC article.
OBJECTIVES: To evaluate the effects of aldosterone antagonists (selective (eplerenone), non-selective (spironolactone or canrenone), or non-steroidal mineralocorticoid antagonists (finerenone)) in adults who have CKD with proteinuria (nephrotic and non-nephrotic range) on: …
OBJECTIVES: To evaluate the effects of aldosterone antagonists (selective (eplerenone), non-selective (spironolactone or canrenone), …
Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.
Yang J, Young MJ. Yang J, et al. Curr Opin Pharmacol. 2016 Apr;27:78-85. doi: 10.1016/j.coph.2016.02.005. Epub 2016 Mar 2. Curr Opin Pharmacol. 2016. PMID: 26939027 Review.
Currently there are only two steroidal MRAs that have been approved for use; spironolactone (and its active metabolite canrenone) and eplerenone. However, the search is on for novel generations of MRAs with increased potency and tissue selectivity. ...
Currently there are only two steroidal MRAs that have been approved for use; spironolactone (and its active metabolite canrenone) and …
Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
Frankenstein L, Seide S, Täger T, Jensen K, Fröhlich H, Clark AL, Seiz M, Katus HA, Nee P, Uhlmann L, Naci H, Atar D. Frankenstein L, et al. Heart Fail Rev. 2020 Mar;25(2):161-171. doi: 10.1007/s10741-019-09832-y. Heart Fail Rev. 2020. PMID: 31364027
From 16 different sources, 14 randomized controlled trials totaling 12,213 patients testing an active treatment of either spironolactone, eplerenone, or canrenone/potassium-canreonate in adults with symptomatic HF due to systolic dysfunction reporting any of the above endp …
From 16 different sources, 14 randomized controlled trials totaling 12,213 patients testing an active treatment of either spironolactone, ep …
Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review.
Mai X, Kometani M, Yoneda T. Mai X, et al. Int J Mol Sci. 2022 Nov 10;23(22):13821. doi: 10.3390/ijms232213821. Int J Mol Sci. 2022. PMID: 36430298 Free PMC article. Review.
The probable factors of cytochrome P-450 reduction, both in microsomes and mitochondria, have also been considered: (1) one of the spironolactone metabolite forms had destructive function, except canrenone, (2) 7alpha-thio-spironolactone was an obligatory intermediate in t …
The probable factors of cytochrome P-450 reduction, both in microsomes and mitochondria, have also been considered: (1) one of the spironola …
The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
Young MJ, Kanki M, Karthigan N, Konstandopoulos P. Young MJ, et al. Endocrinology. 2021 Nov 1;162(11):bqab105. doi: 10.1210/endocr/bqab105. Endocrinology. 2021. PMID: 34050730 Review.
This mini-review will discuss the origins and the development of MRA and highlight how their use has evolved from the "potassium-sparing diuretics" spironolactone and canrenone over 60 years ago, to the more receptor-selective eplerenone and most recently the emergence of …
This mini-review will discuss the origins and the development of MRA and highlight how their use has evolved from the "potassium-sparing diu …
Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis.
Kim J, Miyazaki K, Shah P, Kozai L, Kewcharoen J. Kim J, et al. Healthcare (Basel). 2022 Mar 30;10(4):645. doi: 10.3390/healthcare10040645. Healthcare (Basel). 2022. PMID: 35455823 Free PMC article. Review.
We included studies with all types of MRA therapy including spironolactone and canrenone and found no association between MRA therapy and mortality in SARS-CoV-2 infection (OR = 0.387, 95% CI: 0.134-1.117, p = 0.079)....
We included studies with all types of MRA therapy including spironolactone and canrenone and found no association between MRA therapy …
A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.
Korol S, Mottet F, Perreault S, Baker WL, White M, de Denus S. Korol S, et al. Medicine (Baltimore). 2017 Dec;96(48):e8719. doi: 10.1097/MD.0000000000008719. Medicine (Baltimore). 2017. PMID: 29310346 Free PMC article. Review.
The objective of this review was to assess current knowledge on MRAs' influence (spironolactone, eplerenone, and canrenone) on glucose homeostasis and the risk of diabetes. METHOD: A systematic review was conducted using the Medline database on articles published from 1946 …
The objective of this review was to assess current knowledge on MRAs' influence (spironolactone, eplerenone, and canrenone) on glucos …
14 results